keyword
MENU ▼
Read by QxMD icon Read
search

Pituitary tumour

keyword
https://www.readbyqxmd.com/read/29455199/clinical-features-and-response-to-treatment-of-prolactinomas-in-children-and-adolescents-a-retrospective-single-centre-analysis-and-review-of-the-literature
#1
Thomas Breil, Catherine Lorz, Daniela Choukair, Janna Mittnacht, Ioana Inta, Daniela Klose, Jessica Jesser, Egbert Schulze, Markus Bettendorf
BACKGROUND: Paediatric prolactinomas are rare. The aim of this study was to investigate the clinical features and outcome of paediatric patients with prolactinomas. METHODS: In this single-centre retrospective analysis, clinical, biochemical, and radiological features of all paediatric patients with pituitary adenomas diagnosed between 2000 and 2016 were evaluated. RESULTS: Among 21 patients with pituitary adenomas, 12 patients with prolactinomas (median age 14...
February 16, 2018: Hormone Research in Pædiatrics
https://www.readbyqxmd.com/read/29449689/current-and-emerging-therapies-for-pnets-in-patients-with-or-without-men1
#2
REVIEW
Morten Frost, Kate E Lines, Rajesh V Thakker
Pancreatic neuroendocrine tumours (PNETs) might occur as a non-familial isolated endocrinopathy or as part of a complex hereditary syndrome, such as multiple endocrine neoplasia type 1 (MEN1). MEN1 is an autosomal dominant disorder characterized by the combined occurrence of PNETs with tumours of the parathyroids and anterior pituitary. Treatments for primary PNETs include surgery. Treatments for non-resectable PNETs and metastases include biotherapy (for example, somatostatin analogues, inhibitors of receptors and monoclonal antibodies), chemotherapy and radiological therapy...
February 16, 2018: Nature Reviews. Endocrinology
https://www.readbyqxmd.com/read/29430977/amenorrhoea-and-reversible-infertility-due-to-obstructive-hydrocephalus-literature-review-and-case-report
#3
Kimberly Hamilton, Bermans Iskandar
BACKGROUND: Endocrine abnormalities are well-recognized consequences of intracranial pathology such as pituitary tumours. Less commonly, hydrocephalus may lead to dysfunction of the endocrine system, presenting as amenorrhoea or precocious puberty. We present a case report and literature review of hydrocephalus causing endocrine abnormalities including reversible infertility. CASE DESCRIPTION: A 34 year-old female presented with amenorrhoea and infertility. MRI showed a third ventricular mass and hydrocephalus...
February 12, 2018: British Journal of Neurosurgery
https://www.readbyqxmd.com/read/29383476/apoplexy-in-nonfunctioning-pituitary-adenomas
#4
REVIEW
Luiz Eduardo Wildemberg, Andrea Glezer, Marcello D Bronstein, Mônica R Gadelha
Pituitary apoplexy is an uncommon event, occurring due to the infarction and/or haemorrhage usually of a previously unknown pituitary adenoma. It can occur in all adenoma subtypes but is more common in nonfunctioning pituitary adenomas. The physiopathology is not completely clear, and precipitating factors, such as major surgeries, anticoagulant use or pituitary dynamic tests, can be found in up to 40% of patients. The clinical presentation is characterized by a rapid onset with a headache as the main symptom, but visual disturbances can also be present as well as meningism and intracranial hypertension...
January 31, 2018: Pituitary
https://www.readbyqxmd.com/read/29378769/neuropsychiatric-and-metabolic-aspects-of-dopaminergic-therapy-perspectives-from-an-endocrinologist-and-a-psychiatrist
#5
Anastasia P Athanasoulia-Kaspar, Kathrin H Popp, Gunter K Stalla
The dopaminergic treatment represents the primary treatment in prolactinomas which are the most common pituitary adenomas and account for about 40% of all pituitary tumours with an annual incidence of six to ten cases per million population. The dopaminergic treatment includes ergot and non ergot derivatives with high affinity for the dopamine receptors D1 or/and D2. Through the activation of the dopaminergic pathway on pituitary lactotrophs, the dopamine agonists inhibit the prolactin synthesis and secretion, therefore normalizing the prolactin levels and restoring eugonadism, but also lead to tumour shrinkage...
January 29, 2018: Endocrine Connections
https://www.readbyqxmd.com/read/29373931/neurosurgical-image-giant-pituitary-adenoma-and-multiple-aneurysms
#6
Himanshu Agarwal, Chandril Chugh, Saraj Singh, Prakash Singh
Pituitary adenomas are associated with intracranial aneurysms. Giant non-functioning pituitary adenomas with aneurysms in their vicinity pose technical surgical challengesas aneurysm rupture can be catastrophic during surgery. We present the case of a middle aged women who presented with progressive visual loss in both eyes caused by a giant pituitary adenoma compressing the optic chiasma. She also had associated mirror image carotid aneurysms embedded in the tumour. They were successfully coiled preoperatively and the tumour was removed safely with improvement of her symptoms...
January 26, 2018: British Journal of Neurosurgery
https://www.readbyqxmd.com/read/29373118/prognostic-implications-of-telomerase-expression-in-pituitary-adenomas
#7
F Tortosa, S M Webb
OBJECTIVES: To analyse the prognostic value of telomerase expression in patients with pituitary adenomas (PAs) followed-up for at least 8 years. PATIENTS AND METHODS: A retrospective study was conducted of samples from 51 PAs (40 typical and 11 atypical) from patients who underwent transsphenoidal surgery between 2006 and 2008 and from 10 normal pituitary glands obtained by autopsy. Telomerase expression was assessed by immunohistochemistry, correlating the expression with that of Ki-67 and p53...
January 17, 2018: Revista Clínica Española
https://www.readbyqxmd.com/read/29363000/pituitary-xanthogranulomas-clinical-features-radiological-appearances-and-post-operative-outcomes
#8
R Ved, N Logier, P Leach, J S Davies, C Hayhurst
BACKGROUND: Xanthogranulomas are inflammatory masses most commonly found at peripheral sites such as the skin. Sellar and parasellar xanthogranulomas are rare and present a diagnostic challenge as they are difficult to differentiate from other sellar lesions such as craniopharyngiomas and Rathke's cleft cysts pre-operatively. Their radiological imaging features are yet to be clearly defined, and clinical outcomes after surgery are also uncertain. This study reviews clinical presentation, radiological appearances, and clinical outcomes in a cohort of patients with pituitary xanthogranulomas...
January 23, 2018: Pituitary
https://www.readbyqxmd.com/read/29361984/changes-in-biodistribution-on-68-ga-dota-octreotate-pet-ct-after-long-acting-somatostatin-analogue-therapy-in-neuroendocrine-tumour-patients-may-result-in-pseudoprogression
#9
Martin H Cherk, Grace Kong, Rodney J Hicks, Michael S Hofman
BACKGROUND: To evaluate the effects of long-acting somatostatin analogue (SSA) therapy on 68 Ga-DOTA-octreotate (GaTate) uptake at physiological and metastatic sites in neuroendocrine tumour (NET) patients. METHODS: Twenty-one patients who underwent GaTate PET/CT before and after commencement of SSA therapy were reviewed. Maximum standardized uptake values (SUVmax) were measured in normal organs. Changes in uptake of 49 metastatic lesions in 12 patients with stable disease were also compared...
January 24, 2018: Cancer Imaging: the Official Publication of the International Cancer Imaging Society
https://www.readbyqxmd.com/read/29351945/concurrent-endocrine-neoplasias-in-dogs-and-cats-a-retrospective-study-2004-2014
#10
Laura Beatrice, Felicitas Schär Boretti, Nadja S Sieber-Ruckstuhl, Claudia Mueller, Claudia Kümmerle-Fraune, Monika Hilbe, Paula Grest, Claudia E Reusch
Multiple endocrine neoplasia (MEN) is a well-known syndrome in human medicine, whereas only a few cases of concurrent endocrine neoplasias have been reported in dogs and cats. The aim of this study was to evaluate the prevalence of concurrent endocrine neoplasias in dogs and cats at our clinic, identify possible breed and sex predispositions and investigate similarities with MEN syndromes in humans. Postmortem reports of 951 dogs and 1155 cats that died or were euthanased at the Clinic for Small Animal Internal Medicine, University of Zurich, between 2004 and 2014 were reviewed, and animals with at least two concurrent endocrine neoplasias and/or hyperplasias were included...
January 19, 2018: Veterinary Record
https://www.readbyqxmd.com/read/29334118/markers-of-proliferation-and-invasiveness-in-somatotropinomas
#11
Agata Baldys-Waligorska, Iga Wierzbicka, Grzegorz Sokolowski, Dariusz Adamek, Filip Golkowski
IntroductionIn the search for markers of invasiveness of pituitary adenomas, we studied the expression of Ki-67 antigen, TOPO 2A (topoisomerase 2 alpha), AIP (Aryl Hydrocarbon Receptor-Interacting Protein) and VEGF (Vascular Endothelial Growth Factor) in somatotropinomas.Material and MethodsWe retrospectively studied a group of 31 patients who underwent pituitary tumour surgery. Expression of Ki-67, TOPO 2A, AIP and VEGF in surgical specimens was determined by immunohistochemistry. Relations between quantitatively determined markers and clinical symptoms, tumour features, and MR imaging, were analysed...
January 15, 2018: Endokrynologia Polska
https://www.readbyqxmd.com/read/29330228/treatment-of-aggressive-pituitary-tumours-and-carcinomas-results-of-a-european-society-of-endocrinology-ese-survey-2016
#12
Ann I McCormack, Olaf Dekkers, Stephan Petersenn, Vera Popovic, Jacqueline Trouillas, Gerald Raverot, Pia Burman
OBJECTIVE: To collect outcome data in a large cohort of patients with aggressive pituitary tumours (APT)/carcinomas (PC), and specifically report effects of temozolomide (TMZ) treatment. DESIGN: Electronic survey to ESE members Dec 2015-Nov 2016. RESULTS: Reports on 165 patients (40 PC, 125 APT) were obtained. Median age at diagnosis was 43 (range 4-79) years. 69% of the tumours were clinically functioning, and the most frequent immunohistochemical subtype were corticotroph tumours (45%)...
January 12, 2018: European Journal of Endocrinology
https://www.readbyqxmd.com/read/29319131/temozolomide-therapy-for-aggressive-pituitary-crooke-s-cells-corticotropinoma-causing-cushing-s-disease-a-case-report-with-literature-review
#13
Aleksandra Gilis-Januszewska, Małgorzata Wilusz, Jacek Pantofliński, Renata Turek-Jabrocka, Grzegorz Sokołowski, Anna Sowa-Staszczak, Łukasz Kluczyński, Dorota Pach, Grzegorz Zieliński, Alicja Hubalewska-Dydejczyk
AbstractContext: Aggressive pituitary tumours causing Cushing's Disease are very rare, difficult to treat, and usually resistant to conventional therapy. There is growing evidence for the use of temozolomide (TZM), an alkylating chemotherapeutic agent, as first line chemotherapy in tumours resistant to repeated neurosurgery, radiotherapy and adrenalectomy. OBJECTIVE: To present the response to TMZ in a rare case of an aggressive pituitary tumour in the course of Cushing's Disease and to review the literature referring to similar cases...
January 10, 2018: Endokrynologia Polska
https://www.readbyqxmd.com/read/29299820/malignant-transformation-in-non-functioning-pituitary-adenomas-pituitary-carcinoma
#14
REVIEW
Nèle Lenders, Ann McCormack
Non-functioning pituitary carcinomas (NFPC) are defined as tumours of adenophyseal origin with craniospinal or systemic dissemination, with the absence of a hormonal hypersecretion syndrome. These are a histologically heterogenous group of tumours, comprising gonadotroph, null cell, "silent" tumours of corticotroph, somatotroph or lactotroph cell lineages as well as plurihormonal Pit-1 tumours. NFPC are exceedingly rare, and hence few cases have been described. This review has identified 38 patients with NFPC reported in the literature...
January 3, 2018: Pituitary
https://www.readbyqxmd.com/read/29259039/both-invasiveness-and-proliferation-criteria-predict-recurrence-of-non-functioning-pituitary-macroadenomas-after-surgery-a-retrospective-analysis-of-a-monocentric-cohort-of-120-patients
#15
Julie Lelotte, Anne Jouret-Mourin, Edward Fomekong, Alex Michotte, Christian Raftopoulos, Dominique Maiter
INTRODUCTION: Additional robust criteria to predict early postoperative recurrence of non-functioning pituitary macroadenomas (NFMAs) are needed. Recently, a new classification of pituitary tumours has been proposed which is based on both radiological and histological criteria and allows the grading into 5 groups of different potential aggressiveness. The aim of this study was to use this classification to further characterize predictive factors of recurrence in an independent series of NFMA...
December 19, 2017: European Journal of Endocrinology
https://www.readbyqxmd.com/read/29239034/succinate-dehydrogenase-sdh-deficient-neoplasia
#16
REVIEW
Anthony J Gill
The succinate dehydrogenase (SDH) complex is a key respiratory enzyme composed of four subunits: SDHA, SDHB, SDHC and SDHD. Remarkably, immunohistochemistry for SDHB becomes negative whenever there is bi-alleic inactivation of any component of SDH, which is very rare in the absence of syndromic disease. Therefore, loss of SDHB immunohistochemistry serves as a marker of syndromic disease, usually germline mutation of one of the SDH subunits. Tumours which show loss of SDHB expression are termed succinate dehydrogenase-deficient...
January 2018: Histopathology
https://www.readbyqxmd.com/read/29239033/what-s-new-in-pituitary-pathology
#17
REVIEW
Sylvia L Asa, Ozgur Mete
The increasing recognition of pituitary disorders and their impact on quality of life and longevity has made understanding of this small gland a subject of paramount importance. Pituitary pathology has seen many significant studies that indicate progress in identification and classification of pituitary lesions, as well as improved management strategies for patients. In this review, we outline six major areas of advances: (i) changes in terminology from 'adenoma' to 'pituitary neuroendocrine tumour'; (ii) reclassification of hormone-negative tumours based on transcription factor expression that defines lineage; (iii) updates in new pathogenetic mechanisms, including those that underlie rare lesions such as X-LAG and pituitary blastoma; (iv) clarification of hypophysitis due to immunotherapy, xanthomatous hypophysitis due to rupture of a Rathke's cleft cyst and IgG4 disease as the cause of inflammatory pseudotumour; (v) the consolidation of pituicytoma variants, including spindle cell oncocytoma and granular cell tumour based on thyroid transcription factor-1 (TTF-1) reactivity; and (vi) the pathogenetic mechanisms that distinguish papillary from adamantinomatous craniopharyngioma...
January 2018: Histopathology
https://www.readbyqxmd.com/read/29234591/reproductive-hormone-analyses-and-effects-of-adjuvant-zoledronic-acid-in-early-breast-cancer-an-azure-big-01-04-sub-study
#18
Caroline Wilson, Samantha Hinsley, Helen Marshall, David Cameron, Richard Bell, David Dodwell, Robert E Coleman
Purpose: Adjuvant bisphosphonates have been shown to improve disease outcomes in early breast cancer in women who are postmenopausal at the start of treatment. We explored the influence of pretreatment serum levels of reproductive hormones in the hypothalamic-pituitary-gonadal (HPG) axis from a subset of patients included in the AZURE trial to investigate their impact on disease recurrence and whether reproductive hormone measurements are of value in selecting patients for treatment with adjuvant zoledronic acid...
November 2017: Journal of Bone Oncology
https://www.readbyqxmd.com/read/29193251/which-patients-with-gynaecomastia-require-more-detailed-investigation
#19
S N Ali, C N Jayasena, A H Sam
Gynaecomastia may be due to medication, chronic liver or kidney disease, hypogonadism (primary or secondary to pituitary disease) or hyperthyroidism. Having excluded these aetiologies, it is imperative to be vigilant for underlying malignancy causing gynaecomastia. These include human chorionic gonadotrophin-secreting testicular and extratesticular tumours and oestrogen-secreting testicular tumours and feminising adrenal tumours.
March 2018: Clinical Endocrinology
https://www.readbyqxmd.com/read/29180744/stem-cell-senescence-drives-age-attenuated-induction-of-pituitary-tumours-in-mouse-models-of-paediatric-craniopharyngioma
#20
Jose Mario Gonzalez-Meljem, Scott Haston, Gabriela Carreno, John R Apps, Sara Pozzi, Christina Stache, Grace Kaushal, Alex Virasami, Leonidas Panousopoulos, Seyedeh Neda Mousavy-Gharavy, Ana Guerrero, Mamunur Rashid, Nital Jani, Colin R Goding, Thomas S Jacques, David J Adams, Jesus Gil, Cynthia L Andoniadou, Juan Pedro Martinez-Barbera
Senescent cells may promote tumour progression through the activation of a senescence-associated secretory phenotype (SASP), whether these cells are capable of initiating tumourigenesis in vivo is not known. Expression of oncogenic β-catenin in Sox2+ young adult pituitary stem cells leads to formation of clusters of stem cells and induction of tumours resembling human adamantinomatous craniopharyngioma (ACP), derived from Sox2- cells in a paracrine manner. Here, we uncover the mechanisms underlying this paracrine tumourigenesis...
November 28, 2017: Nature Communications
keyword
keyword
88408
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"